Published in J Med Chem on February 28, 2002
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev (2013) 3.44
The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors. Br J Pharmacol (2013) 2.29
Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology (2008) 1.69
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs (2008) 1.56
Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology (2009) 1.39
Getting in shape: controlling peptide bioactivity and bioavailability using conformational constraints. ACS Chem Biol (2012) 1.26
Integrin-mediated transforming growth factor-beta activation, a potential therapeutic target in fibrogenic disorders. Am J Pathol (2009) 1.25
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer (2012) 1.21
Tumor Targeting via Integrin Ligands. Front Oncol (2013) 1.15
Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer (2011) 1.06
The use of one-bead one-compound combinatorial library technology to discover high-affinity αvβ3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle. Mol Cancer Ther (2010) 0.95
Synthesis and characterization of a high-affinity {alpha}v{beta}6-specific ligand for in vitro and in vivo applications. Mol Cancer Ther (2009) 0.94
Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors. Biol Open (2012) 0.91
Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner. Clin Exp Metastasis (2007) 0.90
Oxidative stress induced mechanisms in the progression of periodontal diseases and cancer: a common approach to redox homeostasis? Cancers (Basel) (2010) 0.87
Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities. PLoS One (2010) 0.86
Vascular endothelial growth factor pathway. Pharmacogenet Genomics (2010) 0.86
Combining molecular targeted agents with radiation therapy for malignant gliomas. Onco Targets Ther (2013) 0.85
Relative binding affinities of integrin antagonists by equilibrium dialysis and liquid chromatography-mass spectrometry. ACS Med Chem Lett (2014) 0.85
Chemically programmed antibodies targeting multiple alpha(v) integrins and their effects on tumor-related functions in vitro. Bioconjug Chem (2011) 0.84
Small-molecule-modified surfaces engage cells through the αvβ3 integrin. ACS Chem Biol (2012) 0.82
Encapsidated atom-transfer radical polymerization in Qβ virus-like nanoparticles. ACS Nano (2014) 0.80
Isolation of radial glia-like neural stem cells from fetal and adult mouse forebrain via selective adhesion to a novel adhesive peptide-conjugate. PLoS One (2011) 0.80
The role of integrins in TGFβ activation in the tumour stroma. Cell Tissue Res (2016) 0.80
Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential. Toxicon (2011) 0.79
Structure Activity Relationships of αv Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents. ACS Med Chem Lett (2014) 0.79
A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins. Sci Rep (2017) 0.78
Selective Detection of RGD-Integrin Binding in Cancer Cells Using Tip Enhanced Raman Scattering Microscopy. Anal Chem (2016) 0.78
Identification of putative drug targets for human sperm-egg interaction defect using protein network approach. BMC Syst Biol (2015) 0.77
New agents targeting angiogenesis in glioblastoma. Chemother Res Pract (2011) 0.77
Dimerization of a phage-display selected peptide for imaging of αvβ6- integrin: two approaches to the multivalent effect. Theranostics (2014) 0.77
Calpha-H...O = C hydrogen bonds contribute to the specificity of RGD cell-adhesion interactions. BMC Struct Biol (2005) 0.76
Solid-phase synthesis and fluorine-18 radiolabeling of cycloRGDyK. Org Biomol Chem (2016) 0.75
Ex vivo expansion of circulating CD34(+) cells enhances the regenerative effect on rat liver cirrhosis. Mol Ther Methods Clin Dev (2016) 0.75
Exploring the Role of RGD-Recognizing Integrins in Cancer. Cancers (Basel) (2017) 0.75
Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients. Cancers (Basel) (2017) 0.75
RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials (2003) 5.34
Activation of integrin function by nanopatterned adhesive interfaces. Chemphyschem (2004) 4.66
Cell spreading and focal adhesion dynamics are regulated by spacing of integrin ligands. Biophys J (2007) 3.57
Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med (2005) 3.12
[18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem (2004) 2.20
Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. J Nucl Med (2004) 2.14
N-methylation of peptides: a new perspective in medicinal chemistry. Acc Chem Res (2008) 2.02
Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res (2006) 1.96
Perspectives on NMR in drug discovery: a technique comes of age. Nat Rev Drug Discov (2008) 1.95
WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem (2006) 1.94
Lateral spacing of integrin ligands influences cell spreading and focal adhesion assembly. Eur J Cell Biol (2005) 1.93
An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol Cell (2009) 1.90
Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem (2010) 1.87
The RGD motif in fibronectin is essential for development but dispensable for fibril assembly. J Cell Biol (2007) 1.81
Impact of order and disorder in RGD nanopatterns on cell adhesion. Nano Lett (2009) 1.75
Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry (2003) 1.69
Asymmetric activation of the hsp90 dimer by its cochaperone aha1. Mol Cell (2010) 1.65
A conserved spider silk domain acts as a molecular switch that controls fibre assembly. Nature (2010) 1.65
The N-terminal domain of p53 is natively unfolded. J Mol Biol (2003) 1.62
Ligands for mapping alphavbeta3-integrin expression in vivo. Acc Chem Res (2009) 1.60
Impact of local versus global ligand density on cellular adhesion. Nano Lett (2011) 1.58
Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues. Angew Chem Int Ed Engl (2008) 1.48
Carbohydrate-based mimetics in drug design: sugar amino acids and carbohydrate scaffolds. Chem Rev (2002) 1.46
Protein repellent properties of covalently attached PEG coatings on nanostructured SiO(2)-based interfaces. Biomaterials (2007) 1.44
Induction of cell polarization and migration by a gradient of nanoscale variations in adhesive ligand spacing. Nano Lett (2008) 1.43
PET Imaging of Integrin αVβ3 Expression. Theranostics (2011) 1.41
The architecture of functional modules in the Hsp90 co-chaperone Sti1/Hop. EMBO J (2012) 1.36
PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem (2011) 1.28
Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol (2009) 1.27
Hsp90 is regulated by a switch point in the C-terminal domain. EMBO Rep (2009) 1.24
Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res (2008) 1.21
Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies. J Am Chem Soc (2010) 1.20
NMR chemical shift perturbation study of the N-terminal domain of Hsp90 upon binding of ADP, AMP-PNP, geldanamycin, and radicicol. Chembiochem (2003) 1.20
Cooperativity in adhesion cluster formation during initial cell adhesion. Biophys J (2008) 1.18
Optimized selective N-methylation of peptides on solid support. J Pept Sci (2006) 1.18
The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction. Angew Chem Int Ed Engl (2002) 1.17
First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res (2004) 1.15
Tumor Targeting via Integrin Ligands. Front Oncol (2013) 1.15
Hsp12 is an intrinsically unstructured stress protein that folds upon membrane association and modulates membrane function. Mol Cell (2010) 1.14
PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med (2011) 1.13
Intrinsic inhibition of the Hsp90 ATPase activity. J Biol Chem (2006) 1.13
BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. J Biol Chem (2009) 1.12
The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides. Mol Pharm (2011) 1.10
Transmembrane signal transduction of the alpha(IIb)beta(3) integrin. Protein Sci (2002) 1.10
In support of the BMRB. Nat Struct Mol Biol (2012) 1.09
p53--a natural cancer killer: structural insights and therapeutic concepts. Angew Chem Int Ed Engl (2006) 1.08
A computational model of transmembrane integrin clustering. Structure (2004) 1.08
Cellular unbinding forces of initial adhesion processes on nanopatterned surfaces probed with magnetic tweezers. Nano Lett (2006) 1.08
Telethonin deficiency is associated with maladaptation to biomechanical stress in the mammalian heart. Circ Res (2011) 1.07
Convenient synthesis of N-methylamino acids compatible with Fmoc solid-phase peptide synthesis. J Org Chem (2005) 1.07
Structural analysis of the interaction between Hsp90 and the tumor suppressor protein p53. Nat Struct Mol Biol (2011) 1.05
Cell interactions with hierarchically structured nano-patterned adhesive surfaces. Soft Matter (2009) 1.05
Synthesis and stereochemical assignment of DNA spore photoproduct analogues. Chemistry (2006) 1.04
Synthesis of novel 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA) derivatives for chemoselective attachment to unprotected polyfunctionalized compounds. Chemistry (2007) 1.03
Photoswitched cell adhesion on surfaces with RGD peptides. J Am Chem Soc (2005) 1.03
N-methylation of peptides and proteins: an important element for modulating biological functions. Angew Chem Int Ed Engl (2012) 1.03
Mimicking cellular environments by nanostructured soft interfaces. Nano Lett (2007) 1.02
3-Substituted indolizine-1-carbonitrile derivatives as phosphatase inhibitors. Bioorg Med Chem Lett (2005) 1.02
Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J Nucl Med (2005) 1.02
Characterization of human saposins by NMR spectroscopy. Biochemistry (2006) 1.02
Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction. Biol Chem (2003) 1.01
N-methylated cyclic pentaalanine peptides as template structures. J Am Chem Soc (2006) 1.01
Intestinal permeability of cyclic peptides: common key backbone motifs identified. J Am Chem Soc (2012) 1.00
Diffusion NMR spectroscopy: folding and aggregation of domains in p53. Chembiochem (2005) 1.00
FOSL1 controls the assembly of endothelial cells into capillary tubes by direct repression of αv and β3 integrin transcription. Mol Cell Biol (2013) 1.00
68Ga-NODAGA-RGD is a suitable substitute for (18)F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol (2012) 0.99
Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4. J Med Chem (2011) 0.98
Design of selective peptidomimetic agonists for the human orphan receptor BRS-3. J Med Chem (2003) 0.96
Solid-phase synthesis of 1,3-azole-based peptides and peptidomimetics. Org Lett (2006) 0.96
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur J Nucl Med Mol Imaging (2007) 0.96
Transcriptional regulation by antitermination. Interaction of RNA with NusB protein and NusB/NusE protein complex of Escherichia coli. J Mol Biol (2002) 0.96
Cooperative binding of p53 to DNA: regulation by protein-protein interactions through a double salt bridge. Angew Chem Int Ed Engl (2005) 0.96
The CLIP/CLAP-HSQC: pure absorptive spectra for the measurement of one-bond couplings. J Magn Reson (2008) 0.95
Evidence for hetero-association of transmembrane helices of integrins. FEBS Lett (2004) 0.95
Polymeric substrates with tunable elasticity and nanoscopically controlled biomolecule presentation. Langmuir (2010) 0.95
Design and chemical synthesis of integrin ligands. Methods Enzymol (2007) 0.94
Comparison of cyclic RGD peptides for αvβ3 integrin detection in a rat model of myocardial infarction. EJNMMI Res (2013) 0.94
NMR studies on the substrate-binding domains of the thermosome: structural plasticity in the protrusion region. J Mol Biol (2004) 0.94
Titanium implant materials with improved biocompatibility through coating with phosphonate-anchored cyclic RGD peptides. Chembiochem (2005) 0.94
Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Des (2003) 0.93
RGD-peptides for tissue engineering of articular cartilage. Biomaterials (2002) 0.93
Influence of the internal disulfide bridge on the folding pathway of the CL antibody domain. J Mol Biol (2006) 0.92
Cell adhesion and proliferation on RGD-modified recombinant spider silk proteins. Biomaterials (2012) 0.92
High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett (2002) 0.92
The conformation of cyclo(-D-Pro-Ala4-) as a model for cyclic pentapeptides of the DL4 type. J Am Chem Soc (2006) 0.92
Probing integrin selectivity: rational design of highly active and selective ligands for the alpha5beta1 and alphavbeta3 integrin receptor. Angew Chem Int Ed Engl (2007) 0.92
ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion. Int J Biochem Cell Biol (2005) 0.92
Cell adhesion and polarisation on molecularly defined spacing gradient surfaces of cyclic RGDfK peptide patches. Eur J Cell Biol (2008) 0.91
pH-dependent dimerization and salt-dependent stabilization of the N-terminal domain of spider dragline silk--implications for fiber formation. Angew Chem Int Ed Engl (2011) 0.91
Docking studies on alphavbeta3 integrin ligands: pharmacophore refinement and implications for drug design. J Med Chem (2003) 0.90
Synthesis of N-methylated cyclic peptides. Nat Protoc (2012) 0.90
Introducing lasso peptides as molecular scaffolds for drug design: engineering of an integrin antagonist. Angew Chem Int Ed Engl (2011) 0.90
Guiding plant virus particles to integrin-displaying cells. Nanoscale (2012) 0.90
The solution structure of BMPR-IA reveals a local disorder-to-order transition upon BMP-2 binding. Biochemistry (2008) 0.90
Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem (2007) 0.89
A conformationally frozen peptoid boosts CXCR4 affinity and anti-HIV activity. Angew Chem Int Ed Engl (2012) 0.89
Isothiocyanate-functionalized RGD peptides for tailoring cell-adhesive surface patterns. Biomaterials (2008) 0.88
The structure of a folding intermediate provides insight into differences in immunoglobulin amyloidogenicity. Proc Natl Acad Sci U S A (2008) 0.88
The state of the art of chemical biology. Chembiochem (2009) 0.88
Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). Mol Pharm (2014) 0.88